FDA Approves Sanofi, Regeneron Treatment for Chronic Rhinosinusitis with Nasal Polyposis

Date : 06/26/2019 @ 6:30PM
Source : Dow Jones News
Stock : Sanofi (SNY)
Quote : 46.71  0.0 (0.00%) @ 11:32AM

FDA Approves Sanofi, Regeneron Treatment for Chronic Rhinosinusitis with Nasal Polyposis

Historical Stock Chart

6 Months : From May 2019 to Nov 2019

Click Here for more Sanofi Charts.

By Michael Dabaie


Sanofi (SNY) and Regeneron Pharmaceuticals Inc. (REGN) said the U.S. Food and Drug Administration approved Dupixent, or dupilumab, for use with other medicines to treat chronic rhinosinusitis with nasal polyposis in adults whose disease isn't controlled.

Sanofi and Regeneron are jointly developing dupilumab under a global collaboration agreement. CRSwNP is a chronic disease of the upper airway that obstructs the sinuses and nasal passages.

Dupilumab is the first biologic medicine for adults with inadequately controlled chronic rhinosinusitis with nasal polyposis, the companies said. Dupixent significantly reduces nasal polyp size and improves congestion and loss of smell, while reducing the need for surgery and systemic corticosteroids, the companies said.


Write to Michael Dabaie at michael.dabaie@wsj.com


(END) Dow Jones Newswires

June 26, 2019 14:15 ET (18:15 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Latest SNY Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.